MedPath

GnRH for Luteal Support in IVF/ICSI/FET Cycles

Phase 4
Recruiting
Conditions
Infertility
Interventions
Drug: placebo
Registration Number
NCT02357654
Lead Sponsor
University Reproductive Associates
Brief Summary

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

Detailed Description

see above

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
350
Inclusion Criteria
  • women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.
Exclusion Criteria
  • day 3 transfers

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placeboplacebo-
GnRH agonistGnRH-
Primary Outcome Measures
NameTimeMethod
Live birth per transfer9 months
Secondary Outcome Measures
NameTimeMethod
clinical pregnancy4 weeks
rates of OHSS4 weeks
implantation rates4 weeks

Trial Locations

Locations (1)

University Reproductive Associates

🇺🇸

Hasbrouck Heights, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath